The nucleophosmin (NPM1) gene encodes for a multifunctional chaperone protein that is
localized in the nucleolus but continuously shuttles between the nucleus and cytoplasm …

NPM1-mutated acute myeloid leukemia (AML) represents the largest molecular subgroup of
adult AML. NPM1-mutated AML is recognizable by molecular techniques and …

NUP98 and NUP214 form chimeric fusion proteins that assemble into phase-separated
nuclear bodies containing CRM1, a nuclear export receptor. However, these nuclear bodies' …

Epigenetic dysregulation is reported in multiple cancers including Ewing sarcoma (EwS).
However, the epigenetic networks underlying the maintenance of oncogenic signaling and …

Gain-of-function mutations in the histone acetylation “reader” eleven-nineteen-leukemia
(ENL), found in acute myeloid leukemia (AML) and Wilms tumor, are known to drive …

The plasma membrane is enriched for receptors and signaling proteins that are accessible
from the extracellular space for pharmacological intervention. Here we conducted a series of …

Acute Myeloid Leukemia (AML) is a highly heterogeneous disease with 3-year patient
survival ranging from 30 to 80%, depending on molecular characteristics. Mutations in …

Mutations in NPM1, also known as nucleophosmin-1, B23, NO38, or numatrin, are seen in
approximately one-third of patients with acute myeloid leukaemia (AML). A plethora of …

Pharmacologic targeting of chromatin-associated protein complexes has shown significant
responses in KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML) but resistance …

The direct targeting of chromatin-associated proteins is increasingly recognized as a
potential therapeutic strategy for the treatment of cancer. In this review, we discuss a …